MedTrace Logo

Dietary Interventions for Irritable Bowel Syndrome

NCT07774923 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-08-20

No results posted yet for this study

Summary

Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction characterized by recurrent abdominal pain and altered bowel habits. Dietary factors may trigger or worsen symptoms such as abdominal pain, bloating, gas, diarrhea, and constipation. This study evaluated and compared the effects of a low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (low-FODMAP) diet and a combined gluten-free and lactose-free diet on symptom severity in adults diagnosed with IBS.

Adults aged 19-64 years with IBS followed one of the two dietary interventions for six weeks. IBS symptom severity was assessed at baseline and at the end of week 6 using the Irritable Bowel Syndrome Symptom Severity Score (IBS-SSS). Dietary adherence was monitored by telephone during the intervention.

Conditions

  • Irritable Bowel Syndrome

Interventions

BEHAVIORAL

Low-FODMAP Diet

Participants followed a low-FODMAP diet for six weeks. Foods high in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols were restricted. Participants received detailed dietary instructions during the initial face-to-face visit. Dietary adherence was monitored by telephone one week after starting the intervention and subsequently at two-week intervals.

BEHAVIORAL

Gluten-Free and Lactose-Free Diet

Participants followed a combined gluten-free and lactose-free diet for six weeks. Foods containing gluten and lactose were excluded. Participants received detailed dietary instructions during the initial face-to-face visit. Dietary adherence was monitored by telephone one week after starting the intervention and subsequently at two-week intervals.

Sponsors & Collaborators

  • Bahçeşehir University

    collaborator OTHER

  • Mersin University

    collaborator OTHER

  • Istanbul Gelisim University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-25
Primary Completion
2025-07-18
Completion
2025-07-18

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07774923 on ClinicalTrials.gov